摘要
晚年抑郁症(LLD)即使在亚综合征阶段,从认知正常(CN)到轻度认知障碍(MCI)表现出高转换率。 [18F] -氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)研究结果在晚年抑郁症身上患者一致,而萎缩被反复描述。因此,我们着手在老年认知正常患者抑郁症状调查氟脱氧葡萄糖代谢和视频差错隐消效果(PVEC)。21 位认知正常患者的阳性项目抑郁类别(DEP)在神经精神问卷调查表上和29位认知正常患者缺少抑郁项(NON-DEP)来自阿尔茨海默氏病影像学倡议支持者。氟脱氧葡萄糖正电子发射断层扫描使用独立正电子发射断层扫描空间,利用成交量体积(VOI)和统计参数图(SPM)方法分析。基于成交量体积和磁共振成像的视频差错隐消被运用于正电子发射断层扫描数据。与裸数据认知正常患者缺少抑郁项相比,抑郁类别项目表现出显著的低额颞叶皮质、后扣带回皮质(PCC)。在以成交量体积和统计参数图方法为基础视频差错隐消在后扣带回皮质有消除意义,在额颞区仍然显著甚至达到意义比如如果发生在在左侧杏仁核。亚综合征抑郁认知正常患者情绪相关脑区的氟脱氧葡萄糖代谢降低,这可能是他们从认知正常到轻度认知障碍转化风险升高相关。在正电子发射断层扫描的分析方法的进步,应该在今后的研究中考虑相应的变化结果,即作为视频差错隐消相关变化独立正电子发射断层扫描空间检测抑郁类别和缺少抑郁项表观代谢差异的科目。此外,在独立正电子发射断层扫描空间以成交量体积为基础的分析将允许更精确的考虑变异的解剖,特别是在皮层下区。
关键词: 老年痴呆症,抑郁症状,氟脱氧葡萄糖正电子发射断层扫描,轻度认知障碍,磁共振成像,部分容积效应校正
Current Alzheimer Research
Title:Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects
Volume: 13 Issue: 5
Author(s): Matthias Brendel, Veronika Reinisch, Eva Kalinowski, Johannes Levin, Andreas Delker and Sonja Därr, Oliver Pogarell, Stefan Förster, Peter Bartenstein, Axel Rominger, Alzheimer’s Disease Neuroimaging Initiative
Affiliation:
关键词: 老年痴呆症,抑郁症状,氟脱氧葡萄糖正电子发射断层扫描,轻度认知障碍,磁共振成像,部分容积效应校正
摘要: Late life depression (LLD) even in subsyndromal stages shows high conversion rates from cognitively normal (CN) to mild cognitive impairment (MCI). Results of [18F]-fluorodesoxyglucose positron-emission-tomography (FDG-PET) were inconsistent in LLD patients, whereas atrophy was repeatedly described. Therefore, we set out to investigate FDG metabolism and the effect of atrophy correction (PVEC) in geriatric CN patients with depressive symptoms. 21 CN subjects with positive item for the depression category (DEP) in the Neuropsychiatric-Inventory-Questionnaire and 29 CN subjects with an absent depression item (NON-DEP) were selected from the ADNI cohort. FDG-PETs were analyzed in individual PET space using volumes-of-interest (VOI) and statistical-parametric-mapping (SPM) approaches. VOI- and MRI-based PVEC were applied to PET data. DEP subjects showed significant hypometabolism in fronto-temporal cortices and the posterior cingulate cortex (PCC) when contrasted against NON-DEP in uncorrected data. Both in VOI- and SPM-based approaches PVEC eliminated significance in PCC, while fronto-temporal regions remained significant or even attained significance such as in case of the left amygdala. Subsyndromally depressed CN subjects had decreased FDG metabolism in mood-related brain regions, which may be relevant to their elevated risk for conversion from CN to MCI. Methodological advances in PET analyses should be considered in future studies as PVEC relevantly changed results of FDG-PET for detecting apparent metabolic differences between DEP and NON-DEP subjects. Furthermore, VOI-based analyses in individual PET space will allow a more accurate consideration of variability in anatomy, especially in subcortical regions.
Export Options
About this article
Cite this article as:
Matthias Brendel, Veronika Reinisch, Eva Kalinowski, Johannes Levin, Andreas Delker and Sonja Därr, Oliver Pogarell, Stefan Förster, Peter Bartenstein, Axel Rominger, Alzheimer’s Disease Neuroimaging Initiative , Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666160314143922
DOI https://dx.doi.org/10.2174/1567205013666160314143922 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design Chemoinformatics Approaches for Traditional Chinese Medicine Research and Case Application in Anticancer Drug Discovery
Current Drug Discovery Technologies Alzheimer's Disease-Like Pathologies and Cognitive Impairments Induced by Formaldehyde in Non-Human Primates
Current Alzheimer Research Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research Cognitive Function and Quality of Life in Mild Thyroid Hormone Deficiency
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Alterations in the Expression of Amyloid Precursor Protein Cleaving Enzymes mRNA in Alzheimer Peripheral Blood
Current Alzheimer Research Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Current Status of Anti-HIV Agents
Current Medicinal Chemistry - Anti-Infective Agents QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease)
Current Pharmaceutical Design Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Preface
Current Psychopharmacology The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets New Thrombin and Factor Xa Inhibitors for Primary and Secondary Prevention of Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Central Nervous System Agents for Ischemic Stroke: Neuroprotection Mechanisms
Central Nervous System Agents in Medicinal Chemistry Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders